Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

NCT04747197 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04747197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04747197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 20, 2021
Completion date
May 11, 2022
Enrollment
17 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration